GlaxoSmithKline Pakistan (KAR:GLAXO) ROCE % : 42.86% (As of Sep. 2024)

View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GlaxoSmithKline Pakistan's annualized ROCE % for the quarter that ended in Sep. 2024 was 42.86%.

GlaxoSmithKline Pakistan ROCE % Historical Data

The historical data trend for GlaxoSmithKline Pakistan's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pakistan ROCE % Chart

GlaxoSmithKline Pakistan Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

28.06

27.48

36.43

22.84

9.45

GlaxoSmithKline Pakistan Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-1.50	27.13	16.98	32.82	42.86

GlaxoSmithKline Pakistan ROCE % Calculation

GlaxoSmithKline Pakistan's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	2183.818	/	( ( (35541.907 - 12908.571)	+	(38130.899 - 14564.719) )	/ 2 )
	=	2183.818	/	( (22633.336	+	23566.18)	/ 2 )
	=	2183.818	/	23099.758
	=	9.45 %

GlaxoSmithKline Pakistan's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	11241.888	/	( ( (43348.799 - 18091.972)	+	(47256.928 - 20054.62) )	/ 2 )
	=	11241.888	/	( ( 25256.827	+	27202.308 )	/ 2 )
	=	11241.888	/	26229.5675
	=	42.86 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

GlaxoSmithKline Pakistan (KAR:GLAXO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GlaxoSmithKline Pakistan ROCE % Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pakistan's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pakistan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

35, Dockyard Road, West Wharf, Karachi, PAK, 74000

Website

https://www.pk.gsk.com

GlaxoSmithKline Pakistan Ltd is engaged in research, development, and manufacturing pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines